caa a22 4500 477057829 CHVBK 20180405111351.0 cr unu---uuuuu 170330e19960301xx s 000 0 eng 10.1007/BF00195931 doi (NATIONALLICENCE)springer-10.1007/BF00195931 An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers [Elektronische Daten] [A. Lönnebo, A. Grahnén, B. Jansson, R. Brundin, A. Ling-Andersson, S.-Å. Eckernäs] The systemic effects of single and multiple doses of inhaled fluticasone propionate (FP) and budesonide were examined in 24 healthy male volunteers (age range 18-29 years). The study was of an open, placebo-controlled, randomized, three-way crossover design. On each study day, multiple blood samples were taken over a 20 h period after drug administration (after a single dose and after the last of seven doses) and area under the curve (AUC0-20) for plasma cortisol and white blood cell (WBC) counts was calculated. Results: The present study shows that multiple dosing with FP 1.0 mg b.i.d. for 3.5 days (seven doses) resulted in a marked cortisol suppression from placebo which, at 55%, was more than double that seen with a single dose (25% suppression). Multiple dosing with budesonide 0.8 mg b.i.d. resulted in a 34% suppression in plasma cortisol compared with a suppression of 26% with a single dose. The increase in systemic activity of FP after multiple dosing is confirmed by both the number of subjects with 0800 hours plasma cortisol values below normal limits and by the changes in WBC and differential counts. Conclusion: The results of the present study confirm previous findings with regard to the more marked systemic effect of FP following multiple dosing as compared with a single dose. This increase in systemic effect from single dosing to multiple dosing is significantly greater for FP than for budesonide. Springer-Verlag, 1996 Corticosteroids nationallicence systemic effects nationallicence plasma cortisol suppression nationallicence white blood cell count nationallicence healthy volunteers nationallicence Lönnebo A. PMC Contract Research AB, Islandgatan 2, S-753 18, Uppsala, Sweden aut Grahnén A. PMC Contract Research AB, Islandgatan 2, S-753 18, Uppsala, Sweden aut Jansson B. PMC Contract Research AB, Islandgatan 2, S-753 18, Uppsala, Sweden aut Brundin R. PMC Contract Research AB, Islandgatan 2, S-753 18, Uppsala, Sweden aut Ling-Andersson A. PMC Contract Research AB, Islandgatan 2, S-753 18, Uppsala, Sweden aut Eckernäs S.-Å PMC Contract Research AB, Islandgatan 2, S-753 18, Uppsala, Sweden aut European Journal of Clinical Pharmacology Springer-Verlag 49/6(1996-03-01), 459-463 0031-6970 49:6<459 1996 49 228 https://doi.org/10.1007/BF00195931 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00195931 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lönnebo A. PMC Contract Research AB, Islandgatan 2, S-753 18, Uppsala, Sweden aut NATIONALLICENCE 700 1- Grahnén A. PMC Contract Research AB, Islandgatan 2, S-753 18, Uppsala, Sweden aut NATIONALLICENCE 700 1- Jansson B. PMC Contract Research AB, Islandgatan 2, S-753 18, Uppsala, Sweden aut NATIONALLICENCE 700 1- Brundin R. PMC Contract Research AB, Islandgatan 2, S-753 18, Uppsala, Sweden aut NATIONALLICENCE 700 1- Ling-Andersson A. PMC Contract Research AB, Islandgatan 2, S-753 18, Uppsala, Sweden aut NATIONALLICENCE 700 1- Eckernäs S.-Å PMC Contract Research AB, Islandgatan 2, S-753 18, Uppsala, Sweden aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 49/6(1996-03-01), 459-463 0031-6970 49:6<459 1996 49 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer